PL3194405T3 - Makrocykliczne inhibitory kinazy lrrk2 - Google Patents
Makrocykliczne inhibitory kinazy lrrk2Info
- Publication number
- PL3194405T3 PL3194405T3 PL15766801T PL15766801T PL3194405T3 PL 3194405 T3 PL3194405 T3 PL 3194405T3 PL 15766801 T PL15766801 T PL 15766801T PL 15766801 T PL15766801 T PL 15766801T PL 3194405 T3 PL3194405 T3 PL 3194405T3
- Authority
- PL
- Poland
- Prior art keywords
- kinase inhibitors
- lrrk2 kinase
- macrocyclic
- macrocyclic lrrk2
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290279 | 2014-09-17 | ||
| PCT/EP2015/071349 WO2016042089A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic lrrk2 kinase inhibitors |
| EP15766801.3A EP3194405B1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic lrrk2 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL3194405T4 PL3194405T4 (pl) | 2019-07-31 |
| PL3194405T3 true PL3194405T3 (pl) | 2019-07-31 |
Family
ID=51752058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15766801T PL3194405T3 (pl) | 2014-09-17 | 2015-09-17 | Makrocykliczne inhibitory kinazy lrrk2 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10377772B2 (enExample) |
| EP (1) | EP3194405B1 (enExample) |
| JP (1) | JP2017529365A (enExample) |
| KR (1) | KR20170048599A (enExample) |
| CN (1) | CN107108641A (enExample) |
| AU (1) | AU2015316801B2 (enExample) |
| BR (1) | BR112017005299A2 (enExample) |
| CA (1) | CA2960777A1 (enExample) |
| DK (1) | DK3194405T3 (enExample) |
| EA (1) | EA032838B1 (enExample) |
| ES (1) | ES2717510T3 (enExample) |
| HU (1) | HUE043972T2 (enExample) |
| IL (1) | IL251054B (enExample) |
| MX (1) | MX2017003470A (enExample) |
| PL (1) | PL3194405T3 (enExample) |
| SG (1) | SG11201701936WA (enExample) |
| TR (1) | TR201904514T4 (enExample) |
| TW (1) | TW201625639A (enExample) |
| WO (1) | WO2016042089A1 (enExample) |
| ZA (1) | ZA201701841B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111221514B (zh) * | 2020-01-13 | 2023-03-03 | 陕西心像信息科技有限公司 | 基于OsgEarth的三维可视化组件实现方法及系统 |
| CN115698020B (zh) * | 2020-01-31 | 2025-02-25 | 昂科迪塞恩精密医药公司(Opm) | 大环rip2-激酶抑制剂 |
| US12545689B2 (en) | 2020-05-06 | 2026-02-10 | Oncodesign Precision Medicine | Macrocyclic LRRK2 kinase inhibitors |
| JP2024512449A (ja) | 2021-03-18 | 2024-03-19 | レ ラボラトワール セルヴィエ | 大環状ｌｒｒｋ２キナーゼ阻害剤 |
| WO2023064768A1 (en) * | 2021-10-11 | 2023-04-20 | Baylor College Of Medicine | G-protein-coupled receptor regulators and methods of use thereof |
| WO2023073013A1 (en) * | 2021-10-27 | 2023-05-04 | H. Lundbeck A/S | Lrrk2 inhibitors |
| WO2023222005A1 (zh) * | 2022-05-18 | 2023-11-23 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其中间体、药物组合物和用途 |
| AR130483A1 (es) | 2022-09-15 | 2024-12-11 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| WO2024218296A1 (en) * | 2023-04-20 | 2024-10-24 | H. Lundbeck A/S | Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors |
| AR132488A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| AR132487A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| AR132486A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| SK283569B6 (sk) | 1993-10-01 | 2003-09-11 | Astra Aktiebolag | Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| HU229024B1 (en) | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| ES2294047T3 (es) | 2000-12-28 | 2008-04-01 | Ono Pharmaceutical Co., Ltd. | Un compuesto de ciclopenta (d) pirazolo(1,5-a) pirimidina como antagonista del receptor de crf. |
| WO2002100399A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| EP2316927B1 (en) | 2004-10-21 | 2014-11-05 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Kaspp (lrrk2) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| FI123725B (fi) | 2005-08-01 | 2013-10-15 | Reijo Viljanen | Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet |
| ES2506040T3 (es) | 2005-11-16 | 2014-10-13 | Cti Biopharma Corp. | Derivados de pirimidina ligados a oxígeno |
| WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| SG179120A1 (en) | 2009-09-29 | 2012-05-30 | Glaxo Group Ltd | Novel compounds |
| KR102015402B1 (ko) * | 2010-05-20 | 2019-08-28 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| PT2760453T (pt) * | 2011-09-30 | 2016-08-02 | Ipsen Pharma Sas | Inibidores macrocíclicos da cinase lrrk2 |
| BR112014007622A2 (pt) * | 2011-09-30 | 2017-04-04 | Oncodesign Sa | inibidores de flt3 cinase macrocíclicos |
-
2015
- 2015-09-17 KR KR1020177010322A patent/KR20170048599A/ko not_active Withdrawn
- 2015-09-17 CA CA2960777A patent/CA2960777A1/en not_active Abandoned
- 2015-09-17 DK DK15766801.3T patent/DK3194405T3/en active
- 2015-09-17 HU HUE15766801A patent/HUE043972T2/hu unknown
- 2015-09-17 TR TR2019/04514T patent/TR201904514T4/tr unknown
- 2015-09-17 JP JP2017515823A patent/JP2017529365A/ja active Pending
- 2015-09-17 ES ES15766801T patent/ES2717510T3/es active Active
- 2015-09-17 MX MX2017003470A patent/MX2017003470A/es unknown
- 2015-09-17 TW TW104130753A patent/TW201625639A/zh unknown
- 2015-09-17 WO PCT/EP2015/071349 patent/WO2016042089A1/en not_active Ceased
- 2015-09-17 EA EA201790626A patent/EA032838B1/ru not_active IP Right Cessation
- 2015-09-17 SG SG11201701936WA patent/SG11201701936WA/en unknown
- 2015-09-17 AU AU2015316801A patent/AU2015316801B2/en not_active Ceased
- 2015-09-17 US US15/511,879 patent/US10377772B2/en not_active Expired - Fee Related
- 2015-09-17 PL PL15766801T patent/PL3194405T3/pl unknown
- 2015-09-17 BR BR112017005299A patent/BR112017005299A2/pt not_active IP Right Cessation
- 2015-09-17 EP EP15766801.3A patent/EP3194405B1/en not_active Not-in-force
- 2015-09-17 CN CN201580061216.1A patent/CN107108641A/zh active Pending
-
2017
- 2017-03-09 IL IL251054A patent/IL251054B/en not_active IP Right Cessation
- 2017-03-15 ZA ZA2017/01841A patent/ZA201701841B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016042089A1 (en) | 2016-03-24 |
| CA2960777A1 (en) | 2016-03-24 |
| SG11201701936WA (en) | 2017-04-27 |
| TR201904514T4 (tr) | 2019-04-22 |
| AU2015316801A1 (en) | 2017-04-27 |
| ZA201701841B (en) | 2019-08-28 |
| IL251054B (en) | 2019-03-31 |
| BR112017005299A2 (pt) | 2017-12-12 |
| HUE043972T2 (hu) | 2019-09-30 |
| DK3194405T3 (en) | 2019-04-15 |
| PL3194405T4 (pl) | 2019-07-31 |
| US10377772B2 (en) | 2019-08-13 |
| JP2017529365A (ja) | 2017-10-05 |
| TW201625639A (zh) | 2016-07-16 |
| IL251054A0 (en) | 2017-04-30 |
| EP3194405A1 (en) | 2017-07-26 |
| EA201790626A1 (ru) | 2017-07-31 |
| CN107108641A (zh) | 2017-08-29 |
| AU2015316801B2 (en) | 2019-03-07 |
| EP3194405B1 (en) | 2018-12-26 |
| KR20170048599A (ko) | 2017-05-08 |
| MX2017003470A (es) | 2017-08-07 |
| US20170240565A1 (en) | 2017-08-24 |
| EA032838B1 (ru) | 2019-07-31 |
| ES2717510T3 (es) | 2019-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| ZA201901034B (en) | Macrocycle kinase inhibitors | |
| IL251784A0 (en) | Bromodomain inhibitors | |
| IL248086A0 (en) | Biaryl kinase inhibitors | |
| EP3172213A4 (en) | Macrocyclic kinase inhibitors and uses thereof | |
| EP3131900A4 (en) | Heterocyclic kinase inhibitors | |
| ZA201701841B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| PT3092227T (pt) | Derivados heterocíclicos bicíclicos como inibidores de bromodomínios | |
| GB201615282D0 (en) | Tankyrase inhibitors | |
| ZA201506327B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| SG11201609350XA (en) | Methods for inhibiting necroptosis | |
| IL258438B (en) | 2-Aminoquinoline derivatives as p70s6 kinase inhibitors | |
| EP3201181A4 (en) | Sphingosine kinase inhibitors | |
| ZA201701331B (en) | Macrocyclic rip2 kinase inhibitors | |
| GB201414116D0 (en) | Benzodiazepine derivatives | |
| GB201404570D0 (en) | Macrocyclic kinase inhibitors | |
| GB201404555D0 (en) | Macrocyclic kinase inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors | |
| GB201519381D0 (en) | Kinase inhibitors | |
| GB201614783D0 (en) | Kinases inhibitors | |
| AU2014903812A0 (en) | Novel kinase inhibitors i | |
| GB201418154D0 (en) | Inhibitors | |
| GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors |